Commentary Published: 01 July 2006 Alzheimer disease research in Japan: public funding Takeshi Iwatsubo, Yasuo Ihara & Ichiro Kanazawa Nature Medicine 12, 778–779 (2006) Cite this article ...

Scientists in Japan may be at the start of a truly monumental accomplishment: a vaccine that can slow or delay the progression of Alzheimer’s disease. In preliminary research released this week ...

Japanese researchers have confirmed a way to predict the onset of Alzheimer’s disease with a high degree of probability, by checking blood for the presence of a certain type of abnormal protein ...

The optimism about Alzheimer’s was palpable in Kyoto, along with the cherry blossoms and beginning of Golden Week. The WHO’s target date of 2025 for finding a cure now seems to be in reach.

Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...

The research was published in the medical journal Alzheimer's Research & Therapy on Nov. 21. In a time of both misinformation and too much information, quality journalism is more crucial than ever.

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

It will make a huge difference.” “If you go back 10 or 15 years, we couldn’t even say for sure that you had Alzheimer’s because it couldn’t be confirmed until autopsy,” says Shallcross.

Meanwhile, 2022 also saw Roche receive a breakthrough designation from the FDA for its in vitro Alzheimer’s test—an amyloid plasma panel that also measures blood levels of phosphorylated tau ...

According to Japan's National Institute of Population and Social Security Research, people aged over 65 are expected to account for 32.3% of the country's population by 2035.

A traditional Japanese diet may help stave off dementia, especially among women, according to new research that demonstrates the benefits of eating fish and drinking green tea.

Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer's disease. The findings from a phase 3 ...